KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $10.7 million.

  • Esperion Therapeutics' Cash from Financing Activities rose 21733.92% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year decrease of 2669.99%. This contributed to the annual value of $86.5 million for FY2024, which is 7139.12% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Cash from Financing Activities stood at $10.7 million, which was up 21733.92% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Cash from Financing Activities ranged from a high of $213.4 million in Q4 2021 and a low of -$30.4 million during Q4 2022
  • For the 5-year period, Esperion Therapeutics' Cash from Financing Activities averaged around $23.4 million, with its median value being $3.7 million (2021).
  • As far as peak fluctuations go, Esperion Therapeutics' Cash from Financing Activities skyrocketed by 354651.81% in 2023, and later tumbled by 381112.48% in 2024.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Cash from Financing Activities stood at $213.4 million in 2021, then crashed by 114.23% to -$30.4 million in 2022, then soared by 114.73% to $4.5 million in 2023, then soared by 682.73% to $35.0 million in 2024, then plummeted by 69.51% to $10.7 million in 2025.
  • Its Cash from Financing Activities stands at $10.7 million for Q3 2025, versus $2.8 million for Q2 2025 and -$7.5 million for Q1 2025.